TrialCurveADIUVO: reconstructed Kaplan–Meier curves
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Diabetes Endocrinol. 2023 Oct;11(10):720–30. doi: 10.1016/S2213-8587(23)00193-6 |
|---|---|
| DOI | 10.1016/S2213-8587(23)00193-6 |
| Registry | NCT00777244 |
| Phase | Phase 3 |
| Conditions | Adrenocortical Carcinoma |
| Interventions | MITOTANE |
| Sponsor | University of Turin, Italy |
| Enrolment | 200 |
| Source licence | Figure published under CC BY 4.0 |
Recurrence-free survival — Intention-to-treat population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Mitotane group not reached; Surveillance group not reached. Survival at 18 months: Mitotane group 86%; Surveillance group 85%. Hazard ratio Mitotane group vs Surveillance group 0.75 (95% CI 0.30–1.87).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Mitotane group | 45 | 8 | not reached |
| Surveillance group | 46 | 11 | not reached |
- Mitotane group vs Surveillance group: reconstructed HR 0.75 (95% CI 0.30–1.87)
Landmark survival (reconstructed)
| Time | Mitotane group | Surveillance group |
|---|---|---|
| 6 mo | 97.8% | 95.7% |
| 12 mo | 88.7% | 91.3% |
| 18 mo | 86.3% | 84.5% |
| 24 mo | 86.3% | 82.0% |
| 36 mo | 83.6% | 79.3% |
| 48 mo | 83.6% | 79.3% |
| 60 mo | 79.4% | 75.8% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.74, reconstructed 0.752 pass
Overall survival — Intention-to-treat population
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Mitotane group not reached; Surveillance group not reached. Survival at 18 months: Mitotane group 95%; Surveillance group 100%. Hazard ratio Mitotane group vs Surveillance group 0.42 (95% CI 0.08–2.16).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Mitotane group | 45 | 2 | not reached |
| Surveillance group | 46 | 5 | not reached |
- Mitotane group vs Surveillance group: reconstructed HR 0.42 (95% CI 0.08–2.16)
Landmark survival (reconstructed)
| Time | Mitotane group | Surveillance group |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 97.7% | 100.0% |
| 18 mo | 95.3% | 100.0% |
| 24 mo | 95.3% | 100.0% |
| 36 mo | 95.3% | 100.0% |
| 48 mo | 95.3% | 94.3% |
| 60 mo | 95.3% | 86.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.46, reconstructed 0.419 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/adiuvo-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/adiuvo-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Diabetes Endocrinol. 2023 Oct;11(10):720–30. doi: 10.1016/S2213-8587(23)00193-6 doi:10.1016/S2213-8587(23)00193-6. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/adiuvo
Report a problem with these data
Related trials
- NCI9673 (Part B): Overall survival; Progression-free survival
- CONFIRM: Overall survival; Progression-free survival
- Convalescent plasma for severe COVID-19 in cancer patients: Overall survival (secondary endpoint)
- GENERATE: Overall survival (planned interim analysis); Overall survival (updated analysis); Progress
- JCOG0905: Disease-free survival; Disease-free survival (good responders); Overall survival; Overall
- JCOG1113 (liver cirrhosis subgroup): Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials